Jonathan Lakey, Ph.D., Joins the Sanguine Corp. in Development of PHER-O2 for Organ and Islet Transplantation.

PASADENA, Calif. -- Sanguine Corp. (OTCBB: SGNC), a biopharmaceutical company focused on the development of oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion, has selected Jonathan Lakey, Ph.D., director of the Clinical Islet Laboratory at the University of Alberta at Edmonton, to help Sanguine's PHER-O2 development program. Lakey and his team at the University of Alberta, developers of the Edmonton Protocol for treatment in Type 1 diabetes, have experience with using PHER-O2 as part of the islet transplant procedure. This protocol is in the process of applying for medical license from the FDA. A meeting of the medical advisory team is scheduled for Oct. 19, 2005 to discuss Lakey's ongoing work with Sanguine and the completion of PHER-O2 testing.

Thomas C. Drees, Ph.D., president and CEO, remarked, "We are extremely excited to have Dr. Lakey join the team in conducting our PHER-O2 development program. As I have mentioned previously, the fragile islet cells culled from donor organs can be severely damaged during organ cold storage or by the drugs given to recipients to prevent rejection; additionally the pancreas itself can be damaged. As a consequence, most islet transplants require two to four donor pancreases to produce enough cells for the recipient to become insulin independent. Our goal, with pursuing this indication, would be to significantly increase the viability of transplant cells, thus increasing the number of islet cells available for successful transplantation. Dr. Lakey's experience in using PHER-O2 by having already completed its animal study, we feel, is paramount toward conducting a rapid and cost-effective program for Sanguine. We look forward to meeting with Dr. Lakey and several members of our medical advisory board on Oct. 19 to continue forward with our development program."

For information related to the Sanguine Corp., contact Investor Relations: Michael Dancy, 801-746-3570, e-mail: [e-mail], or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.